

# Michele Milella

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4228020/michele-milella-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

173  
papers

10,347  
citations

38  
h-index

100  
g-index

188  
ext. papers

12,131  
ext. citations

5.8  
avg, IF

5.47  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 173 | Exercise oncology: It is time to make a change.. <i>Patient Education and Counseling</i> , <b>2022</b> ,   | 3.1  | 0         |
| 172 | ICGC-ARGO precision medicine: familial matters in pancreatic cancer.. <i>Lancet Oncology</i> , <b>2022</b> , 23, 25-26   | 21.7 | 2         |
| 171 | Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona.. <i>Annals of Oncology</i> , <b>2022</b> ,   | 10.3 | 0         |
| 170 | Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy?.. <i>Nutrition</i> , <b>2022</b> , 98, 111637  | 4.8  | 1         |
| 169 | SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 148  | 12.8 | 1         |
| 168 | Evolving pancreatic cancer treatment: From diagnosis to healthcare management.. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 169, 103571   | 7    | 2         |
| 167 | Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research. <i>European Journal of Oncology Nursing</i> , <b>2021</b> , 55, 102061   | 2.8  | 0         |
| 166 | Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.. <i>ESMO Open</i> , <b>2021</b> , 7, 100308  | 6    | 2         |
| 165 | Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different Germline Mutations: New Horizons from Tumor Molecular Profiling. <i>Genes</i> , <b>2021</b> , 12,   | 4.2  | 8         |
| 164 | Targeting KRAS: The Elephant in the Room of Epithelial Cancers. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 638360  | 5.3  | 11        |
| 163 | Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 650293  | 5.3  | 4         |
| 162 | Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 662205  | 5.3  | 1         |
| 161 | Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 672219                                 | 8.4  | 2         |
| 160 | A multimodal approach to cancer-related cachexia: from theory to practice. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 21, 819-826  | 3.5  | 4         |
| 159 | Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19. <i>Infectious Diseases and Therapy</i> , <b>2021</b> , 10, 1579-1590  | 6.2  | 4         |
| 158 | Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. <i>Clinical Oncology</i> , <b>2021</b> , 33, e31-e38   | 2.8  | 8         |
| 157 | Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1583-1592 | 7.4  | 4         |

|     |   |      |    |
|-----|---|------|----|
| 156 | A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma. <i>BMC Cancer</i> , <b>2021</b> , 21, 165                   | 4.8  | 0  |
| 155 | Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface. <i>ESMO Open</i> , <b>2021</b> , 6, 100028  | 6    | 1  |
| 154 | PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 351-360   | 4.9  | 2  |
| 153 | Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report. <i>Immunotherapy</i> , <b>2021</b> , 13, 971-976  | 3.8  | 2  |
| 152 | Exercise prehabilitation in lung cancer: Getting stronger to recover faster. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 1847-1855   | 3.6  | 3  |
| 151 | Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus -paclitaxel for Advanced Pancreatic Adenocarcinoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 688889  | 5.3  | 2  |
| 150 | Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability. <i>Journal of Cancer Education</i> , <b>2021</b> , 1   | 1.8  | 0  |
| 149 | Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients. <i>Pancreatology</i> , <b>2021</b> ,   | 3.8  | 3  |
| 148 | Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. <i>World Journal of Gastrointestinal Surgery</i> , <b>2021</b> , 13, 885-903  | 2.4  | 2  |
| 147 | Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study. <i>Breast</i> , <b>2021</b> , 60, 6-14 | 3.6  | 1  |
| 146 | Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy?. <i>Acta Oncologica</i> , <b>2021</b> , 1-5  | 3.2  | 0  |
| 145 | ASO Author Reflections: Preoperative Nutritional Care: The 'Cinderella' of Surgical Management in Patients with Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 5335-5336   | 3.1  | 1  |
| 144 | Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 5325-5334  | 3.1  | 10 |
| 143 | Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. <i>Cancers</i> , <b>2020</b> , 12,  | 6.6  | 5  |
| 142 | Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 531-542  | 3.5  | 2  |
| 141 | Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 159-169   | 7.5  | 9  |
| 140 | Molecular Tumor Boards in Clinical Practice. <i>Trends in Cancer</i> , <b>2020</b> , 6, 738-744   | 12.5 | 29 |
| 139 | Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). <i>Cancers</i> , <b>2020</b> , 12,                           | 6.6  | 9  |

|     |  |      |    |
|-----|--|------|----|
| 138 | Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. <i>Pathology</i> , <b>2020</b> , 52, 297-309   | 1.6  | 18 |
| 137 | Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. <i>Cancers</i> , <b>2020</b> , 12,   | 6.6  | 26 |
| 136 | From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. <i>Cells</i> , <b>2020</b> , 9,   | 7.9  | 14 |
| 135 | "Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients. <i>PLoS ONE</i> , <b>2020</b> , 15, e0227846   | 3.7  | 5  |
| 134 | Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome. <i>ESMO Open</i> , <b>2020</b> , 5, e000689  | 6    | 4  |
| 133 | Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Clinical implications.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16769-e16769                                    | 2.2  | 1  |
| 132 | Effect of evidence-based nutrition educational intervention on adherence to dietary guidelines (ADG) and weight management among early-stage breast cancer (EBC) patients (pts): A prospective trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 12056-12056 | 2.2  |    |
| 131 | Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?. <i>Oncologist</i> , <b>2020</b> , 25, e555-e569   | 5.69 | 41 |
| 130 | Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. <i>Cancers</i> , <b>2020</b> , 12,  | 6.6  | 28 |
| 129 | High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 588862  | 5.3  | 4  |
| 128 | Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,  | 6.3  | 11 |
| 127 | Exercise Levels and Preferences in Cancer Patients: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,  | 4.6  | 16 |
| 126 | PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,   | 6.3  | 12 |
| 125 | KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2020</b> , 39, 227  | 12.8 | 18 |
| 124 | BRAF status modulates Interleukin-8 expression through a CHOP-dependent mechanism in colorectal cancer. <i>Communications Biology</i> , <b>2020</b> , 3, 546   | 6.7  | 1  |
| 123 | Physical Activity for Oncological Patients in COVID-19 Era: No Time to Relax. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa071   | 4.6  | 4  |
| 122 | Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg. <i>Thrombosis Research</i> , <b>2020</b> , 194, 216-219   | 8.2  | 10 |
| 121 | A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nTRO trial. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920947969                               | 5.4  | 4  |

|     |   |     |    |
|-----|---|-----|----|
| 120 | Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 600940 | 5.3 | 4  |
| 119 | Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 169-185  | 3.8 | 10 |
| 118 | Infections and Immunotherapy in Lung Cancer: A Bad Relationship?. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 22,  | 6.3 | 7  |
| 117 | Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report. <i>Future Science OA</i> , <b>2020</b> , 7, FSO659  | 2.7 | 3  |
| 116 | Running with cancer—A qualitative study to evaluate barriers and motivations in running for female oncological patients <b>2020</b> , 15, e0227846  |     |    |
| 115 | Running with cancer—A qualitative study to evaluate barriers and motivations in running for female oncological patients <b>2020</b> , 15, e0227846  |     |    |
| 114 | Running with cancer—A qualitative study to evaluate barriers and motivations in running for female oncological patients <b>2020</b> , 15, e0227846  |     |    |
| 113 | Running with cancer—A qualitative study to evaluate barriers and motivations in running for female oncological patients <b>2020</b> , 15, e0227846  |     |    |
| 112 | Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , <b>2019</b> , 11,  | 6.6 | 18 |
| 111 | Muscle derangement and alteration of the nutritional machinery in NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 141, 43-53  | 7   | 10 |
| 110 | Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e514-e516                                  | 4.9 | 6  |
| 109 | Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer. <i>Journal of Oncology</i> , <b>2019</b> , 2019, 5373580  | 4.5 | 11 |
| 108 | PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?. <i>Cancers</i> , <b>2019</b> , 11,  | 6.6 | 53 |
| 107 | Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 609-618                    | 7.4 | 18 |
| 106 | Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. <i>Cancers</i> , <b>2019</b> , 11,  | 6.6 | 25 |
| 105 | PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. <i>Cancers</i> , <b>2019</b> , 11,  | 6.6 | 47 |
| 104 | Immuno-evolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. <i>Scientific Reports</i> , <b>2019</b> , 9, 12286  | 4.9 | 15 |
| 103 | Maintenance with lanreotide in small-cell lung cancer expressing somatostatin receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , <b>2019</b> , 134, 121-126  | 5.9 | 1  |

|     |  |      |     |
|-----|--|------|-----|
| 102 | Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e903-e908  | 3.3  | 16  |
| 101 | Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , <b>2019</b> , 12,   | 6.6  | 14  |
| 100 | Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. <i>Cell Death and Disease</i> , <b>2019</b> , 10, 201  | 9.8  | 61  |
| 99  | Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 7652014  | 4.3  | 21  |
| 98  | An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2018</b> , 18, 435-446 | 2.2  | 9   |
| 97  | Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 568-575                       | 8.9  | 9   |
| 96  | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , <b>2018</b> , 19, 521-536   | 21.7 | 315 |
| 95  | Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. <i>Carcinogenesis</i> , <b>2018</b> , 39, 971-980  | 4.6  | 32  |
| 94  | mTOR Cross-Talk in Cancer and Potential for Combination Therapy. <i>Cancers</i> , <b>2018</b> , 10,  | 6.6  | 78  |
| 93  | Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2018</b> , 37, 140  | 12.8 | 22  |
| 92  | Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 11-year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial <b>2018</b> , 6, 7  |      | 191 |
| 91  | Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e945-e951   | 3.3  | 22  |
| 90  | Role of mTOR Signaling in Tumor Microenvironment: An Overview. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,  | 6.3  | 74  |
| 89  | Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2018</b> , 37, 278   | 12.8 | 14  |
| 88  | Renal cancer: new models and approach for personalizing therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2018</b> , 37, 217   | 12.8 | 9   |
| 87  | PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 43013   | 4.9  | 36  |
| 86  | OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S266-S267   | 8.9  | 4   |
| 85  | Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. <i>Scientific Reports</i> , <b>2017</b> , 7, 13024  | 4.9  | 30  |

|    |   |      |     |
|----|---|------|-----|
| 84 | Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. <i>Cell Discovery</i> , <b>2017</b> , 3, 17022   | 22.3 | 44  |
| 83 | Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2896-2898  | 10.3 | 9   |
| 82 | Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. <i>Oncotarget</i> , <b>2017</b> , 8, 108463-108479   | 3.3  | 7   |
| 81 | Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer. <i>Current Medicinal Chemistry</i> , <b>2017</b> , 24, 1383-1402  | 4.3  | 15  |
| 80 | Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 106, 132-42  | 7    | 7   |
| 79 | Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2016</b> , 30, 1507-11  | 4.6  | 6   |
| 78 | Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. <i>Oncotarget</i> , <b>2016</b> , 7, 11332-48   | 3.3  | 36  |
| 77 | The pattern of hMENA isoforms is regulated by TGF- $\beta$ in pancreatic cancer and may predict patient outcome. <i>Oncolmmunology</i> , <b>2016</b> , 5, e1221556  | 7.2  | 15  |
| 76 | Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 77, 109-14   | 3.5  | 8   |
| 75 | Optimizing clinical benefit with targeted treatment in mRCC: "Tumor growth rate" as an alternative clinical endpoint. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 102, 73-81   | 7    | 3   |
| 74 | Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1374-1385   | 21.7 | 818 |
| 73 | Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 2094-100  | 3.1  | 48  |
| 72 | Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , <b>2015</b> , 10, 517-22   | 5    | 32  |
| 71 | PTEN: Multiple Functions in Human Malignant Tumors. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 24  | 5.3  | 284 |
| 70 | A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. <i>Annals of Oncology</i> , <b>2015</b> , 26, 542-7  | 10.3 | 76  |
| 69 | An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1143-61   | 5.9  | 5   |
| 68 | Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. <i>Cell Death and Disease</i> , <b>2015</b> , 6, e1850   | 9.8  | 31  |
| 67 | Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 93, 50-9 | 7    | 11  |

|    |  |      |     |
|----|--|------|-----|
| 66 | Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. <i>Journal of Urology</i> , <b>2015</b> , 193, 41-7   | 2.5  | 43  |
| 65 | Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. <i>Future Oncology</i> , <b>2015</b> , 11, 3159-66  | 3.6  | 9   |
| 64 | Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2015</b> , 34, 156 | 12.8 | 40  |
| 63 | Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0130142 | 3.7  | 339 |
| 62 | Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1341-1348  | 8.9  | 13  |
| 61 | Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. <i>Journal of Urology</i> , <b>2015</b> , 193, 1905-10   | 2.5  | 9   |
| 60 | The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120427   | 3.7  | 8   |
| 59 | Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 12783-95  | 3.3  | 44  |
| 58 | Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2015</b> , 6, 32089-103   | 3.3  | 30  |
| 57 | Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 4788-801  | 5.6  | 48  |
| 56 | Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 2165-9   | 8.7  | 56  |
| 55 | Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 411-417.e4   | 4.9  | 28  |
| 54 | PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. <i>Advances in Biological Regulation</i> , <b>2014</b> , 56, 66-80  | 6.2  | 71  |
| 53 | Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, E121-5  | 1.2  | 7   |
| 52 | Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. <i>Molecular Cancer</i> , <b>2014</b> , 13, 230  | 42.1 | 47  |
| 51 | A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 609-18  | 2.6  | 9   |
| 50 | Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. <i>Future Oncology</i> , <b>2014</b> , 10, 2141-7   | 3.6  | 21  |
| 49 | Second-line chemotherapy in advanced biliary cancer: the present now will later be past. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2443-2444   | 10.3 | 2   |



|    |   |      |      |
|----|---|------|------|
| 48 | Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 11054-63  | 3.3  | 23   |
| 47 | Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 3958-72   | 3.3  | 10   |
| 46 | Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 3944-57   | 3.3  | 42   |
| 45 | Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 471-6   | 3.3  | 19   |
| 44 | Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 1016-22  | 7.5  | 20   |
| 43 | Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , <b>2013</b> , 8, 1381-97   | 6.2  | 6    |
| 42 | Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. <i>Journal of Hematology and Oncology</i> , <b>2013</b> , 6, 67  | 22.4 | 35   |
| 41 | Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2013</b> , 32, 91                            | 12.8 | 15   |
| 40 | Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 2134-42   | 7.5  | 55   |
| 39 | Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. <i>Expert Review of Anticancer Therapy</i> , <b>2013</b> , 13, 697-709  | 3.5  | 12   |
| 38 | Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3609-15  | 7.5  | 64   |
| 37 | PROFILING non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 597-608                            | 4    | 6    |
| 36 | First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 4511-9  | 5.6  | 12   |
| 35 | Imatinib mesylate in thymic epithelial malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 69, 309-15   | 3.5  | 35   |
| 34 | Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. <i>Cell Death and Disease</i> , <b>2012</b> , 3, e440   | 9.8  | 7    |
| 33 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , <b>2012</b> , 13, 239-46 | 21.7 | 3985 |
| 32 | Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. <i>Journal of Molecular Medicine</i> , <b>2012</b> , 90, 1133-44  | 5.5  | 34   |
| 31 | MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. <i>Leukemia</i> , <b>2012</b> , 26, 778-87   | 10.7 | 109  |

|    |   |      |     |
|----|---|------|-----|
| 30 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. <i>Oncotarget</i> , <b>2012</b> , 3, 1068-111   | 3.3  | 250 |
| 29 | Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. <i>Oncotarget</i> , <b>2012</b> , 3, 954-87   | 3.3  | 214 |
| 28 | The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , <b>2012</b> , 90, 667-79  | 5.5  | 46  |
| 27 | Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19 Suppl 1, 52-9  | 3.4  | 14  |
| 26 | Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 1545-57  | 3.5  | 12  |
| 25 | Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3316-27   | 12.9 | 26  |
| 24 | Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. <i>Cell Cycle</i> , <b>2012</b> , 11, 4447-61  | 4.7  | 21  |
| 23 | EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 672-80                                      | 8.9  | 26  |
| 22 | Molecular and genetic bases of pancreatic cancer. <i>Current Drug Targets</i> , <b>2012</b> , 13, 731-43  | 3    | 21  |
| 21 | Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 225-30   | 3.3  | 6   |
| 20 | Maintenance therapy in NSCLC: why? To whom? Which agent?. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2011</b> , 30, 50  | 12.8 | 19  |
| 19 | Circulating autoantibodies to phosphorylated ßenolase are a hallmark of pancreatic cancer. <i>Journal of Proteome Research</i> , <b>2011</b> , 10, 105-12   | 5.6  | 96  |
| 18 | Biology of metastatic renal cell carcinoma. <i>Journal of Cancer</i> , <b>2011</b> , 2, 369-73  | 4.5  | 25  |
| 17 | Lost in translation: bridging the gap between cancer research and effective therapies. <i>Cell Death and Differentiation</i> , <b>2011</b> , 18, 1082-4   | 12.7 | 1   |
| 16 | Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2011</b> , 30, 115   | 12.8 | 23  |
| 15 | Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2011</b> , 30, 54 | 12.8 | 28  |
| 14 | Emerging pathways and future targets for the molecular therapy of pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2011</b> , 15, 1183-96   | 6.4  | 42  |
| 13 | Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2277-85                 | 10.3 | 66  |

|    |  |      |     |
|----|--|------|-----|
| 12 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. <i>Oncotarget</i> , <b>2011</b> , 2, 135-64  | 3.3  | 456 |
| 11 | Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. <i>Oncology</i> , <b>2010</b> , 78, 141-9   | 3.6  | 25  |
| 10 | Early recurrence risk: aromatase inhibitors versus tamoxifen. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 1239-53   | 3.5  | 5   |
| 9  | The mTOR pathway: a new target in cancer therapy. <i>Current Cancer Drug Targets</i> , <b>2010</b> , 10, 484-95  | 2.8  | 134 |
| 8  | Emerging MEK inhibitors. <i>Expert Opinion on Emerging Drugs</i> , <b>2010</b> , 15, 203-23  | 3.7  | 50  |
| 7  | Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. <i>BMC Cancer</i> , <b>2010</b> , 10, 675   | 4.8  | 15  |
| 6  | Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2010</b> , 29, 58 | 12.8 | 41  |
| 5  | An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?. <i>Anti-Cancer Drugs</i> , <b>2010</b> , 21, 459-64  | 2.4  | 6   |
| 4  | Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. <i>European Urology</i> , <b>2010</b> , 58, 906-11  | 10.2 | 48  |
| 3  | Targeting targeted agents: open issues for clinical trial design. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2009</b> , 28, 66   | 12.8 | 15  |
| 2  | Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. <i>Cancer Research</i> , <b>2006</b> , 66, 5549-54   | 10.1 | 285 |
| 1  | Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer. <i>Expert Review of Anticancer Therapy</i> , 1-11  | 3.5  | 0   |